News
US healthcare giant Johnson & Johnson’s subsidiary Janssen-Cilag yesterday announced today new results from the Phase II RedirecTT-1 study evaluating the investigational combination of Talvey ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback